0GZV Stock Chart & Stats
kr215.37
kr0.56(0.30%)
At close: 4:00 PM EST
kr215.37
kr0.56(0.30%)
Day’s Range― - ―
52-Week Rangekr176.30 - kr246.40
Previous CloseN/A
Volume17.36K
Average Volume (3M)108.58K
Market Cap
kr66.73B
Enterprise Valuekr63.06K
Total Cash (Recent Filing)kr2.05B
Total Debt (Recent Filing)kr11.10B
Price to Earnings (P/E)25.0
Beta0.87
Next Earnings
Oct 20, 2026EPS Estimate
2.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.83
Shares Outstanding254,152,370
10 Day Avg. Volume166,450
30 Day Avg. Volume108,580
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr260.00Price Target Upside20.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)12.53
Revenue Forecast (FY)kr35.22B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow supports internal investment, debt service and shareholder returns. The high conversion of earnings into cash also indicates that reported profitability is generally backed by tangible cash generation.
Recurring Installed-Base RevenueAftermarket services, consumables and maintenance create recurring revenue alongside capital-equipment sales. This installed-base model can improve revenue visibility and customer retention across hospital and life-science markets.
Profitability RecoveryThe rebound in EBIT and net margins shows that profitability is recovering from recent weakness. If sustained, improved earnings quality can strengthen cash generation and provide greater financial capacity for operations and investment.
Bears Say
Weak Reported Revenue GrowthThe reported revenue-growth measure is negative, indicating that top-line expansion is not consistently established. Prolonged weak growth could limit operating leverage and make future profit improvement more dependent on cost control.
Margins Below Historical LevelsAlthough profitability has improved, margins remain below earlier peaks, pointing to persistent pressure from product mix, costs or pricing. This reduces confidence that the current recovery represents a fully restored earnings structure.
Higher Leverage And Uneven Cash FlowRising leverage reduces financial flexibility compared with prior years, while uneven historical free cash flow makes cash planning less predictable. Together, these factors could constrain investment or shareholder returns if operating performance weakens.
Getinge News
0GZV FAQ
What was Getinge’s price range in the past 12 months?
Getinge lowest share price was kr176.30 and its highest was kr246.40 in the past 12 months.
What is Getinge’s market cap?
Getinge’s market cap is kr66.73B.
When is Getinge’s upcoming earnings report date?
Getinge’s upcoming earnings report date is Oct 20, 2026 which is in 53 days.
How were Getinge’s earnings last quarter?
Getinge released its earnings results on Jul 17, 2026. The company reported kr3.59 earnings per share for the quarter, beating the consensus estimate of kr2.173 by kr1.417.
Is Getinge overvalued?
According to Wall Street analysts Getinge’s price is currently Undervalued.
Does Getinge pay dividends?
Getinge does not currently pay dividends.
What is Getinge’s EPS estimate?
Getinge’s EPS estimate is 2.52.
How many shares outstanding does Getinge have?
Getinge has 254,152,370 shares outstanding.
What happened to Getinge’s price movement after its last earnings report?
Getinge reported an EPS of kr3.59 in its last earnings report, beating expectations of kr2.173. Following the earnings report the stock price went up 12.064%.
Which hedge fund is a major shareholder of Getinge?
Currently, no hedge funds are holding shares in GB:0GZV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
0GZV Stock 12 Month Forecast
Average Price Target
kr260.00
▲(20.72% Upside)
Technical Analysis
BONESUPPORT HOLDING AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Sedana Medical AB
―








